Important perspective. As more people live longer after a breast cancer diagnosis, the focus must expand beyond treatment to survivorship—long-term effects, monitoring, and quality of life need equal attention.
Most people think breast cancer always forms a lump.
Lobular breast cancer often does not. It can grow in a subtle, diffuse pattern that is harder to detect on imaging.
This difference matters for diagnosis and treatment decisions.
💬 Did you know this?
Breast Cancer Is Not One Disease.
Lobular Breast Cancer Why Many Don't Need Chemo
youtu.be/Hb-DU9tEQCo
The Only Way Coffee Actually Causes Cancer
youtu.be/lf4epOE0rec
Numbers matter, but people matter more. This video highlights the 2026 ACS cancer data — I explain how these trends show up in the clinic and what they mean for patients and caregivers.
youtu.be/Ba4HFqmLICo
An honest conversation with Victoria Goldberg—breast cancer patient and host of the LiveFromStage4 Podcast—about living with stage IV disease.
Now on YouTube.
youtube.com/watch?v=Z_5Y...
Honored to be recognized by ScholarGPS for lifetime contributions to trastuzumab research. HER2-targeted therapy has changed outcomes for patients with breast cancer worldwide. This progress belongs to patients, collaborators, and generations of scientists.
Onward.
scholargps.com
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer | New England Journal of Medicine www.nejm.org/doi/full/10....
🧬 Not everyone with breast cancer—or a family history—actually needs genetic testing. The real question is: how do you know if it’s the right step for you?
Take a look—you might be surprised by who doesn’t need testing, and who definitely should.
youtu.be/ctQZ8Fd7AAE?...
Cancer is overwhelming. But good information can change everything.
Each week, I share short, evidence-based videos on YouTube—breaking down the latest in treatment trends, side effect relief, and survivorship care.
youtu.be/vcetk3Ixiv0
#cancer #bcsm @ascopost.bsky.social @ascocancer.bsky.social
#ASCO25 trials suggest carboplatin may be safely omitted from neoadjuvant therapy in many HER2+ early breast cancers. neoCARHP showed non-inferior pCR without carboplatin and fewer side effects. CompassHER2-pCR confirmed strong THP efficacy, especially in ER− tumors.
#bcsm @ascocancer.bsky.social
Are serial liquid biopsies finally ready for prime time?
If #camizestrant is approved based on #SERENA-6, it would mark the first therapy triggered by a rising #ESR1 mutation before visible recurrence.
That means #ctDNA won’t just monitor—it could guide treatment.
@ascocancer.bsky.social
#bcsm
New hope for hormone-resistant breast cancer?
VERITAC-2 tests a next-gen PROTAC therapy targeting ESR1 mutations.
Breakthrough science at #ASCO25 🎯
@ascocancer.bsky.social @ascopost.bsky.social @erikahamilton9.bsky.social
@bsky.app more than adequately picked up what was lost from Twitter when it comes to medical conferences.
#sabcs24 was a throwback to those old days of following posts, seeing different perspectives on data, and seeing colleagues in San Antonio.
#hcsm has a new home. #oncsm #oncsky
Just returned from #SABCS24—what an incredible experience! It was great reconnecting with old friends, making new connections, and immersing myself in the latest breakthroughs in breast cancer research and treatment. Events like this remind me how collaboration drives progress.
